{"id":"meropenem-and-pralurbactam","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Phlebitis at injection site"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Meropenem works by binding to penicillin-binding proteins and disrupting bacterial cell wall cross-linking, leading to cell lysis and death. Pralurbactam inhibits serine beta-lactamases (including extended-spectrum and carbapenem-resistant variants), preventing the inactivation of meropenem and restoring its activity against resistant gram-negative and gram-positive pathogens.","oneSentence":"Meropenem is a broad-spectrum beta-lactam antibiotic that kills bacteria by inhibiting cell wall synthesis, while pralurbactam is a beta-lactamase inhibitor that protects meropenem from enzymatic degradation by resistant bacteria.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:01.400Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated intra-abdominal infections"},{"name":"Complicated urinary tract infections"},{"name":"Hospital-acquired and ventilator-associated bacterial pneumonia"},{"name":"Infections caused by carbapenem-resistant Enterobacteriaceae (CRE)"}]},"trialDetails":[{"nctId":"NCT07327619","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-01-22","conditions":"Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia","enrollment":420},{"nctId":"NCT07089186","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-04-12","conditions":"Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI)","enrollment":80},{"nctId":"NCT06633718","phase":"PHASE3","title":"Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-10-31","conditions":"Intra-abdominal Infections","enrollment":786}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Meropenem and Pralurbactam","genericName":"Meropenem and Pralurbactam","companyName":"Qilu Pharmaceutical Co., Ltd.","companyId":"qilu-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Meropenem is a broad-spectrum beta-lactam antibiotic that kills bacteria by inhibiting cell wall synthesis, while pralurbactam is a beta-lactamase inhibitor that protects meropenem from enzymatic degradation by resistant bacteria. Used for Complicated intra-abdominal infections, Complicated urinary tract infections, Hospital-acquired and ventilator-associated bacterial pneumonia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}